OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC

December 8th 2023

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Dr Kadia on Targeting the IRAK4 Pathway in AML

December 8th 2023

Tapan M. Kadia, MD, discusses targeting the IRAK4 pathway in patients with acute myeloid leukemia and highlights the importance of utilizing targeted therapies in the treatment of patients with hematologic malignancies.

Dr Tolaney on Sequencing Available ADCs in Breast Cancer

December 8th 2023

Sara M. Tolaney, MD, MPH, discusses the current utilization of antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative breast cancer, highlighting the question of sequencing among available agents.

Dr Cortés on Analyzing Outcomes With T-DXd in HER2+ Breast Cancer With Brain Metastases

December 7th 2023

Javier Cortés, MD, PhD, discusses the rationale for analyzing outcomes with trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who have brain metastases.

Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer

December 7th 2023

Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.

Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer

December 7th 2023

Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.

Dr Stein on the Development of Targeted Therapies in Splicing Mutant Hematologic Malignancies

December 7th 2023

Eytan M. Stein, MD, discusses the ongoing development and investigation of therapies targeting splicing mutations in hematologic malignancies.

Dr Monk on the Investigation of B7-H4–Directed Vedotin ADCs in Gynecologic Cancers

December 7th 2023

Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.

Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast Cancer

December 6th 2023

Jason Jincong Freeman, discusses mortality differences across various racial groups in male patients with stage I, II, or III breast cancer.

Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast Cancer

December 6th 2023

Heather A. Parsons, MD, MPH, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.

Dr Wen on the Evaluation of Tovorafenib in Young Patients with Low-Grade Glioma

December 5th 2023

Patrick Y. Wen, MD, discusses the efficacy of the pan-RAF inhibitor tovorafenib in children and young adults with low-grade glioma and highlights the importance of continual clinical research in this disease.

Dr Drilon on the Potential Benefit of Taletrectinib in ROS1+ NSCLC

December 5th 2023

Alexander Drilon, MD, discusses the potential benefit of taletrectinib in patients with ROS1-positive non–small cell lung cancer.

Dr Shu on Advances in Adjuvant Therapy For Early-Stage NSCLC

December 5th 2023

Catherine Ann Shu, MD, discusses key therapeutic advances in the adjuvant setting for patients with early-stage non–small cell lung cancer.

Dr Goy on the Influence of High-Risk Features on Treatment Decision-Making in MCL

December 5th 2023

Andre Goy, MD, discusses the prevalence of high-risk clinical features in patients with mantle cell lymphoma and their influence on treatment approaches.

Dr Marquina on the Importance of Referring Patients With GIST to Specialized Sarcoma Centers

December 5th 2023

Gloria Marquina, MD, PhD, as well as the need to consider ongoing clinical trials for patients with gastrointestinal stromal tumors vs treatment with the current second-line standard-of-care agent sunitinib.

Dr Maksimovic on a Novel Preclinical Model of Bone Metastasis in ccRCC

December 5th 2023

Stefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.

Dr Agrawal on First-Line Treatment Approaches in HER2+ Breast Cancer

December 5th 2023

Laila S. Agrawal, MD, discusses the primary approaches for treating patients with metastatic HER2-positive breast cancer, and highlights the continued exploration of trastuzumab deruxtecan for this patient population.

Dr Tarantino on the Potential Significance of SGN-B7H4V in Breast Cancer

December 4th 2023

Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.

Dr Bestvina on the Management of AEs Associated With Repotrectinib in ROS1+ NSCLC

December 4th 2023

Christine Bestvina, MD, discusses strategies for managing adverse effects associated with the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.

Dr Karam on Key Kidney Cancer Takeaways From the 2023 IKCS

December 1st 2023

Jose A. Karam, MD, FACS, discusses key takeaways from the 2023 International Kidney Cancer Symposium.